ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "psoriasis"

  • Abstract Number: 966 • 2018 ACR/ARHP Annual Meeting

    Central Triage Clinic for Psoriatic Arthritis – Performance of Triage Methods

    Lihi Eder1, Keith Colaco2, Jensen Yeung3, Chandra Farrer4 and Dana Jerome3, 1Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, 2Institute of Medical Science, University of Toronto, Toronto, ON, Canada, 3University of Toronto, Women's College Hospital, Toronto, ON, Canada, 4Rheumatology, Women's College Hospital, Toronto, ON, Canada

    Background/Purpose: Accurate triage methods for patients with psoriasis who have musculoskeletal symptoms could lead to earlier access to rheumatology care for patients with psoriatic arthritis…
  • Abstract Number: 1608 • 2018 ACR/ARHP Annual Meeting

    The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease

    Curtis Sobchak1, Shadi Akhtari2, Paula Harvey2, Dafna D Gladman3, Vinod Chandran4, Richard J. Cook5 and Lihi Eder6, 1Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, 3Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Krembil Research Institute & University of Toronto, Toronto, ON, Canada, 5Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 6Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada

    Background/Purpose: Patients with psoriatic disease (PsD) are at a high risk of developing cardiovascular events (CVE). The performance of clinical algorithms for cardiovascular risk stratification,…
  • Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting

    Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis

    Josef S. Smolen1, David Shrom2, Chen-Yen Lin2, Julie Birt2, Georg Schett3 and Alice B Gottlieb4, 1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 2Eli Lilly and Company, Indianapolis, IN, 3Medical Clinic 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, 4Department of Dermatology, New York Medical College, New York, NY

    Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…
  • Abstract Number: 1614 • 2018 ACR/ARHP Annual Meeting

    Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis

    Anwar Albasri1, Justine Y. Ye2, Cheryl F. Rosen3, Vinod Chandran2, Dafna D Gladman4 and Lihi Eder5, 1Rheumatology, University of Toronto, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada

    Background/Purpose: Enthesitis is one of the hallmarks of psoriatic arthritis (PsA) and may be the initial site of musculoskeletal inflammation. Enthesitis affects up to 50…
  • Abstract Number: 2447 • 2018 ACR/ARHP Annual Meeting

    Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs

    Enrique R Soriano1, Hugo Madariaga2, Oswaldo Castañeda3, Gustavo Citera4, Emilce E Schneeberger4, Mario H Cardiel5, Thijs Hendrikx6, Daniela Graham7, Harry Shi6 and Dario Ponce de Leon8, 1Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Clínica del Sur, Arequipa, Peru, 3Clínica Anglo Americana, Lima, Peru, 4Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 5Centro de Investigación Clínica de Morelia, Morelia, Mexico, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Lima, Peru

    Background/Purpose: Non-alcoholic fatty liver disease, characterized by hepatic steatosis (HS), is a very common form of chronic liver disease in many countries. Limited data are…
  • Abstract Number: 2567 • 2018 ACR/ARHP Annual Meeting

    Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-Naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results through Week 24 from a Phase 3 Study

    M. Elaine Husni1, Philip J. Mease2, Soumya D Chakravarty3, Shelly Kafka4, Diane D. Harrison5, Dennis Parenti4, Lilianne Kim5, Kim Hung Lo5, Elizabeth C Hsia6 and Arthur Kavanaugh7, 1Cleveland Clinic, Cleveland, OH, 2Swedish Medical Center & U of Wash School of Medicine, Seattle, WA, 3Janssen Scientific Affairs, LLC/Drexel U School of Medicine, Horsham/Phila, PA, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Janssen Research & Development, LLC, Spring House, PA, 6Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, 7UCSD, San Diego, CA

    Background/Purpose: GO-VIBRANT was a Phase 3 trial of intravenous (IV) golimumab (GLM) in adult patients (pts) w/active psoriatic arthritis (PsA). To evaluate improvement in skin,…
  • Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting

    Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls

    Ralf G. Thiele1, Yahui Grace Chiu2, Nelson Huertas3, Dongge Li4, Changyong Feng5, Sharon Moorehead6, Cristy Bell7 and Christopher T. Ritchlin8, 1Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, 3Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, 4Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, 5Statistics, University of Rochester, Rochester, NY, 6Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, 7Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 8Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY

    Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
  • Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting

    Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs

    Philip J Mease1, Joel Kremer2, Stanley Cohen3, Jeffrey R Curtis4, Christina Charles-Schoeman5, Edward V Loftus6, Jeffrey D Greenberg7, Niki Palmetto8, Keith S Kanik9, Daniela Graham9, Cunshan Wang9, Pinaki Biswas8, Gary Chan10, Ryan DeMasi10, Hernan Valdez8, Thijs Hendrikx10 and Thomas V Jones10, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 3Metroplex Clinical Research Center, Dallas, TX, 4University of Alabama, Birmingham, AL, 5University of California, Los Angeles, CA, 6Mayo Clinic, Rochester, MN, 7Corrona, LLC, Southborough, MA, 8Pfizer Inc, New York, NY, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
  • Abstract Number: 625 • 2017 ACR/ARHP Annual Meeting

    Rapid Onset of Efficacy in Patients with Active Psoriatic Arthritis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase III Clinical Trials

    Atul A. Deodhar1, Kim A. Papp2, Catherine Shuler3, So Young Park3 and Tore K. Kvien4, 1Oregon Health & Science University, Portland, OR, 2K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, 3Eli Lilly and Company, Indianapolis, IN, 4Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Rapid onset of clinical improvement is an important attribute of treatment success for patients with PsA. These analyses evaluate the speed of onset of…
  • Abstract Number: 639 • 2017 ACR/ARHP Annual Meeting

    Clinical and Sonographic Analysis of Patients with Psoriasis without Musculoskeletal Complaints. Preeliminary Results of a Prospective Study: The PRE-Psa Cohort

    Andrea Cuervo1, Julio Ramírez2, Merce Alsina3, Raimon Sanmarti4 and Juan D. Cañete5, 1Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, 2Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 3Dermatology Dpt, Hospital Clinic de Barcelona, Barcelona, Spain, 4Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, 5Arthritis Unit. Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain

    Background/Purpose: Early diagnosis in psoriatic arthritis (PsA) is mandatory in order to initiate early therapy and prevent disability. Around 20% of patients with Psoriasis (PsO)…
  • Abstract Number: 882 • 2017 ACR/ARHP Annual Meeting

    A New Model of Care for Improving Early Rheumatology Access of Psoriatic Arthritis Patients

    Keith Colaco1,2, Dana Jerome3, Jensen Yeung4,5, Noah Ivers6,7,8, Carol Kitai7, Chandra Farrer3 and Lihi Eder1,9, 1Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, 2Institute of Medical Science, University of Toronto, Toronto, ON, Canada, 3Rheumatology, Women's College Hospital, Toronto, ON, Canada, 4Dermatology, Women's College Hospital, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 7Women's College Hospital, Toronto, ON, Canada, 8Family and Community Medicine, University of Toronto, Toronto, ON, Canada, 9Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: The prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients is high, with delays in diagnosis contributing to poor patient outcomes. We aimed to…
  • Abstract Number: 989 • 2017 ACR/ARHP Annual Meeting

    Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis

    Jeffrey A. Sparks1, Tamara Lesperance2, Neil A. Accortt3 and Daniel H. Solomon4, 1Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2DOCS Global, Inc., North Wales, PA, 3Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) increase the risk of cardiovascular (CV) disease. However, it is…
  • Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting

    Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso

    Philip J Mease1, Carol J. Etzel2, Jeffrey Lisse3, April W Armstrong4, William J Huster3, Sabrina Rebello2, Rhiannon Dodge2, Talia M Muram3, Sarah Al Sawah3, Mwangi J Murage3, Jeffrey D Greenberg2 and William Malatestinic3, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3Eli Lilly and Company, Indianapolis, IN, 4Keck School of Medicine, University of Southern California, Los Angeles, CA

    Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…
  • Abstract Number: 1557 • 2017 ACR/ARHP Annual Meeting

    Treatment Patterns in Psoriatic Arthritis: Experience from a Real-World Setting

    Martin Brom1, Sebastian Moyano1, Florencia Beatriz Mollerach2, Luciano Fernando Lo Giudice3, Maria Laura Acosta Felquer1, Marina Scolnik4, Santiago Ruta4 and Enrique R Soriano5, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Rheumatology section, Internal Medicine Unit, Hospital Italiano de Buenos Aires and Fundacion PM Catoggio, CABA, Argentina, 4Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, 5Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Both EULAR (European League Against Rheumatism) and GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recently published treatment guidelines for Psoriatic…
  • Abstract Number: 2309 • 2017 ACR/ARHP Annual Meeting

    Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis

    Cynthia K. Manos1,2, Rui Xiao3, Timothy G. Brandon1, Alexis Ogdie4 and Pamela F. Weiss5,6, 1Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, PA, 3Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, 4Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, 5Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, 6Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis.  It…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology